Advertisement

Drugs

, Volume 33, Supplement 4, pp 5–8 | Cite as

Pharmacokinetics of Various Preparations of Organic Nitrates

  • Jens P. Kampmann
Section 1: Pharmacokinetics of Nitrates

Summary

The pharmacokinetics of different formulations of glyceryl trinitrate, isosorbide dinitrate, isosorbide 5-mononitrate and isosorbide 2-mononitrate are reviewed.

Keywords

Glyceryl Trinitrate Isosorbide Isosorbide Dinitrate Organic Nitrate Mononitrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abshagen U. Pharmacokinetics of ISDN, sustained release ISDN and IS-5-MN. In Cohn JN, Rittinghausen R (Eds) Mononitrates. International Boehringer Mannheim Symposium, pp. 53–66, Springer-Verlag, Berlin, 1984Google Scholar
  2. Abshagen U, Spörl-Radun S. First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. European Journal of Clinical Pharmacology 19: 423–429, 1981PubMedCrossRefGoogle Scholar
  3. Abshagen U, Betzien G, Endele R, Kaufmann B. Pharmacokinetics of intravenous and oral isosorbide-5-mononitrate. European Journal of Clinical Pharmacology 20: 269–275, 1981aPubMedCrossRefGoogle Scholar
  4. Abshagen U, Spörl-Radun S, Betzien G, Kaufmann B, Endele R. Pharmakokinetik, Wirkung und Verträglichkeit von Isosorbiddinitrat und Isosorbid-5-Mononitrat bei gesunden Versuchpersonen. Medizinische Welt 32: 508–516, 1981bPubMedGoogle Scholar
  5. Armstrong PW, Armstrong JA, Marks GS. Blood levels after sublingual nitroglycerin. Circulation 59: 585–588, 1979PubMedCrossRefGoogle Scholar
  6. Armstrong PW, Armstrong JA, Marks GS. Pharmacokinetic-hemodynamic studies of intravenous nitroglycerins in congestive cardiac failure. Circulation 62: 160–166, 1980PubMedCrossRefGoogle Scholar
  7. Bashir A, Lewis MJ, Henderson AH. Pharmacokinetic studies of various preparations of glyceryl trinitrate. British Journal of Clinical Pharmacology 14: 779–784, 1982PubMedCrossRefGoogle Scholar
  8. Boegart MG. Clinical pharmacokinetics of organic nitrates. Clinical Pharmacokinetics 8: 410–421, 1983CrossRefGoogle Scholar
  9. Boegart MG, Rosseel MT, Boelaert J, Daneeis R. Fate of isosorbide dinitrate and mononitrates in patients with renal failure. European Journal of Clinical Pharmacology 21: 73–76, 1981CrossRefGoogle Scholar
  10. Curry SH, Aburawi SM. Analysis, disposition and pharmacokinetics of nitroglycerin. Biopharmaceutics and Drug Disposition 6: 235–280, 1985CrossRefGoogle Scholar
  11. Curry SH, Kwon H-R, Perrin JH, Culp JR, Pepine CJ, et al. Plasma nitroglycerin concentrations and hemodynamic effects of sublingual, ointment, and controlled-release forms of nitroglycerin. Clinical Pharmacology and Therapeutics 36: 765–772, 1984PubMedCrossRefGoogle Scholar
  12. Fung H-L. Nitrate formulations and drug delivery systems —an overview. Zeitschrift für Kardiologie 74 (Suppl. 4): 4–9, 1985PubMedGoogle Scholar
  13. Fung H-L, McNiff EF, Ruggirello D, Darke A, Thadani U, et al. Kinetics of isosorbide dinitrate and relationships to pharmacological effects. British Journal of Clinical Pharmacology 11: 579–590, 1981PubMedCrossRefGoogle Scholar
  14. Givant Y, Sulman FG. Quantitation of nitroglycerin in human blood after administration by sustained release. Experientia 34: 643–644, 1978PubMedCrossRefGoogle Scholar
  15. Imhoff PR, Sieber A, Hodler J, Måuller P, Ott B, et al. Plasma concentrations and haemodynamic effects of nitroglycerin during and after intravenous infusion in healthy volunteers. European Journal of Clinical Pharmacology 23: 99–106, 1982CrossRefGoogle Scholar
  16. Kösters W, Klotschkoff P, Abshagen U. Pharmakokinetik von Isosorbide-5-Mononitrat bei Patienten mit fortgeschrittener Niereninsufficienz. Medizinische Welt 32: 521–523, 1981PubMedGoogle Scholar
  17. McAllister A, Mosberg H, Settlage JA, Steiner JA. Plasma levels of nitroglycerin generated by three nitroglycerin patch preparations, Nitradisc, Transiderm-Nitro, and Nitro-Dur and one ointment formulation, Nitrobid. British Journal of Clinical Pharmacology 21: 365–369, 1986PubMedCrossRefGoogle Scholar
  18. McNiff GF, Yacobi A, Young-Chang FM, Golden LH, Goldfarb A, et al. Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects. Journal of Pharmaceutical Science 70: 1054–1058, 1981CrossRefGoogle Scholar
  19. Major RM, Taylor T, Chasseaud LF, Darragh A, Lambe RF. Isosorbide 5-mononitrate kinetics. Clinical Pharmacokinetics and Therapeutics 35: 653–659, 1984CrossRefGoogle Scholar
  20. Mannebach H, Ohlmeier H, v. Möllendorff E, Gleichmann U, Abshagen U. Steady-state Kinetik von Isosorbid-5-Mononitrat bei Patienten mit koronarer Herzkrankenheit. Medizinische Welt 32: 517–520, 1981PubMedGoogle Scholar
  21. Morrison RA, Wiegand U-W, Jähnchen E, Höhmann D, Bechtold H, et al. Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina. Clinical Pharmacology and Therapeutics 33: 747–756, 1983PubMedCrossRefGoogle Scholar
  22. Nyberg G, Blychert L-O, Jonsson UE. Pharmacokinetics of isosorbide-5-mononitrate in a controlled-release (Durules) formulation. British Journal of Clinical Pharmacology 20: 541P, 1985Google Scholar
  23. Olivari M-T, Cohn JN. Cutaneous administration of nitroglycerin: a review. Pharmacotherapy 3: 149–157, 1983PubMedGoogle Scholar
  24. Pitt WA, Friedman RG, Gross SA, Glassman J, Keating EC, et al. Effects of intravenous nitroglycerin on hemodynamics of congestive heart failure. Angiology 33: 294–301, 1982PubMedCrossRefGoogle Scholar
  25. Platzer R, Reutemann G, Galeazzi RL. Pharmacokinetics of intravenous isosorbide-dinitrate. Journal of Pharmacokinetics and Biopharmaceutics 10: 575–586, 1982PubMedGoogle Scholar
  26. Sorkin EM, Brogden RN, Romankiewicz JA. Intravenous glyceryl trinitrate (nitroglycerin). Drugs 27: 45–80, 1984PubMedCrossRefGoogle Scholar
  27. Spörl-Radun S, Betzien G, Kaufmann B, Liede V, Abshagen U. Effects and pharmacokinetics of isosorbide dinitrate in normal men. European Journal of Clinical Pharmacology 18: 237–244, 1980PubMedCrossRefGoogle Scholar
  28. Steudel HC, Volkenandt M, Steudel AT. Pharmacokinetics of isosorbide-5-mononitrate after oral and intravenous administration in patients with liver cirrhosis. First results. Zeitschrift für Kardiologie 72 (Suppl. 3): 24–28, 1983PubMedGoogle Scholar
  29. Straehl P, Galleazzi RL. Isosorbide dinitrate bioavailability, kinetics and metabolism. Clinical Pharmacology and Therapeutics 38: 140–149, 1985PubMedCrossRefGoogle Scholar
  30. Straehl P, Galleazzi RL, Soliva M. Isosorbide 5-mononitrate kinetics after intravenous and oral dosing. Clinical Pharmacology and Therapeutics 36: 485–492, 1984PubMedCrossRefGoogle Scholar
  31. Taylor T, Chasseaud LF, Major R, Doyle E, Darragh A. Isosorbide 5-mononitrate pharmacokinetics in humans. Biopharmaceutics and Drug Disposition 2: 255–263, 1981CrossRefGoogle Scholar
  32. Wei JY, Reid PR. Quantitative determination of trinitroglycerin in human plasma. Circulation 59: 588–592, 1979PubMedCrossRefGoogle Scholar
  33. Wood SG, John BA, Chasseaud LF, et al. Metabolic fate of 14C-isosorbide 5-mononitrate in humans. Arzneimittel-Forschung 34: 1031–1035, 1984PubMedGoogle Scholar

Copyright information

© ADIS Press Limited 1987

Authors and Affiliations

  • Jens P. Kampmann
    • 1
  1. 1.Medical Department P.Bispebjerg HospitalCopenhagen NVDenmark

Personalised recommendations